GlassScriptPhysician profile
Phillip Malvasi
NPI 1376690438
$3,347.94
in general payments reported to CMS, 2019-2025
26 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $124 · 2021: $285 · 2022: $366 · 2023: $432 · 2024: $347 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $812.95 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $491.08 | 2019-2024 | |
| Novo Nordisk INC | $328.16 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $244.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $207.80 | 2019-2021 | |
| Abbvie INC. | $188.06 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.22 | 2019-2023 | Synjardy, Jardiance |
| Lilly USA, LLC | $115.72 | 2019-2024 | Jardiance, Emgality |
| Kowa Pharmaceuticals America, INC. | $105.47 | 2019-2023 | Livalo, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $97.46 | 2019-2024 | Eliquis, Camzyos |
| Daiichi Sankyo INC. | $77.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $73.27 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $69.65 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $67.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $49.52 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $41.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.21 | 2023 | Trulance, Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $38.89 | 2022 | |
| Merck Sharp & Dohme LLC | $38.86 | 2019-2021 | |
| Genentech USA, INC. | $33.95 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $22.53 | 2019 | |
| Impel Pharmaceuticals INC. | $15.28 | 2022 | |
| Lundbeck LLC | $14.73 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.94 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.13 | 2023 | Edarbi |
| Biohaven Pharmaceuticals, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Malvasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.